Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
acetyl-Ala-4-nitroanilide + H2O
acetyl-Ala + 4-nitroaniline
-
-
-
ir
actin + H2O
?
-
degradation at pH 4.0
-
?
Ala-4-methylcoumaryl-7-amide + H2O
Ala + 7-amino-4-methylcoumarin
-
-
-
ir
alpha-N-benzoyl-DL-Arg-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-Arg + beta-naphthylamine
-
-
-
?
alpha-N-benzoyl-DL-arginine-2-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + 2-naphthylamine
-
-
-
-
?
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
alpha-neoendorphin + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
Arg-7-amido-4-methylcoumarin + H2O
L-arginine + 7-amino-4-methylcoumarin
Arg-7-amido-4-trifluoromethylcoumarin + H2O
Arg + 7-amino-4-trifluoromethylcoumarin
fluorogenic cathepsin H substrate
-
-
?
azocasein + H2O
?
-
-
-
-
ir
benzoyl-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-Arg + 7-amino-4-methylcoumarin
-
-
-
ir
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
benzoyl-L-Phe-L-Arg-7-amido-4-methylcoumarin + H2O
benzoyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
benzoyl-L-Phe-L-Val-L-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin + H2O
benzyloxycarbonyl-Phe-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzyloxycarbonyl-Pro-Ala-Ala-Ala-Pro + H2O
benzyloxycarbonyl-Pro-Ala-Ala-Ala + Pro
-
-
-
ir
benzyloxycarbonyl-Pro-Ala-Ala-Ala-Pro-NH2 + H2O
benzyloxycarbonyl-Pro-Ala-Ala-Ala + Pro-NH2
-
-
-
ir
bone morphogenetic protein 4 + H2O
?
-
-
-
-
?
bradykinin + H2O
?
-
no aminopeptidase activity, endopeptidase activity after prolonged incubation
-
?
citrulline-4-methylcoumaryl-7-amide + H2O
citrulline + 7-amino-4-methylcoumarin
-
-
-
ir
demorphin + H2O
?
-
no aminopeptidase activity, endopeptidase activity after prolonged incubation
-
?
dynorphin(1-13) + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
dynorphin(1-6) + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
Fibronectin + H2O
?
-
-
-
?
Gly-beta-naphthylamide + H2O
Gly + beta-naphthylamine
-
very poor substrate
-
?
H2N-Arg-7-amido-4-methylcoumarin + H2O
H2N-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Ala-beta-naphthylamide + H2O
L-Ala + beta-naphthylamine
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-4-methylcoumaryl-7-amide + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
L-Arg-beta-naphthylamide + H2O
L-Arg + beta-naphthylamine
-
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
L-Leu-beta-naphthylamide + H2O
L-Leu + beta-naphthylamine
-
-
-
?
L-leucyl-2-naphthylamide + H2O
L-leucine + 2-naphthylamine
-
-
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
L-Lys-beta-naphthylamide + H2O
L-Lys + beta-naphthylamine
-
-
-
?
L-Met-beta-naphthylamide + H2O
L-Met + beta-naphthylamine
-
-
-
?
L-Pro-beta-naphthylamide + H2O
L-Pro + beta-naphthylamine
-
very poor substrate
-
?
L-Ser-beta-naphthylamide + H2O
L-Ser + beta-naphthylamine
-
-
-
?
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
Leu-2-naphthylamide + H2O
leucine + 2-naphthylamine
-
-
-
?
Leu-4-methylcoumaryl-7-amide + H2O
Leu + 7-amino-4-methylcoumarin
-
-
-
ir
Leu-enkephalin + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
Lys-4-methylcoumaryl-7-amide + H2O
Lys + 7-amino-4-methylcoumarin
-
-
-
ir
Lys-Arg-(Met)enkephalin + H2O
Lys-Arg + (Met)enkephalin
Lys-bradykinin + H2O
?
-
preferentially aminopeptidase activity, endoeptidase activity after prolonged incubation
-
?
Lys-Lys-(Met)enkephalin + H2O
Lys-Lys + (Met)enkephalin
Met-2-naphthylamide + H2O
Met + 2-naphthylamine
-
189% activity of substrate Leu-2-N-naphthylamine
-
ir
myofibrillar protein + H2O
?
-
-
-
-
?
myosin heavy chain + H2O
?
-
degradation at pH 4.0
-
?
neurotensin + H2O
?
-
no aminopeptidase activity, endopeptidase activity after prolonged incubation
-
?
pro-granzyme B + H2O
granzyme B + ?
-
cathepsin H has pro-granzyme B convertase activity in vitro
-
-
?
pro-surfactant protein B-EGFP fusion protein + H2O
?
-
cleavage 13 amino acids upstream of the NH2-terminus of mature surfactant protein B, and at the boundary between surfactant protein and C-terminal peptide
-
-
?
succinyl-Ala-Ala-4-nitroanilide + H2O
succinyl-Ala-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Ala-Ala-4-nitroanilide + H2O
succinyl-Ala-Ala-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Ala-Ala-Ala-4-nitroanilide + H2O
succinyl-Ala-Ala-Ala-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Ala-Ala-Ala-Ala-4-nitroanilide + H2O
succinyl-Ala-Ala-Ala-Ala-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Ala-Pro-4-nitroanilide + H2O
succinyl-Ala-Ala-Pro + 4-nitroaniline
-
-
-
ir
succinyl-Ala-Pro-Ala-4-nitroanilide + H2O
succinyl-Ala-Pro-Ala + 4-nitroaniline
-
-
-
ir
succinyl-Pro-Ala-Ala-4-nitroanilide + H2O
succinyl-Pro-Ala-Ala + 4-nitroaniline
-
-
-
ir
surfactant protein B + H2O
?
-
-
-
-
?
talin + H2O
?
-
cathepsin H cleaves the N-terminus of the talin F0 head domain
-
-
?
tropomyosin + H2O
?
-
degradation at pH 4.0
-
?
troponin I + H2O
?
-
degradation at pH 4.0, little degradation at pH 5.o-5.6
-
?
VALSLKISIGNVVKTMQFEPST + H2O
?
-
the peptide mimicks the N-terminus of the talin F0 head domain
-
-
?
Z-L-Phe-L-Arg-4-methylcoumaryl-7-amide + H2O
?
-
no substrate for wild type enzyme, endopeptidase activity of mutant T11_E18del-cathepsin H
-
?
Z-L-Phe-L-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-L-Phe-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
additional information
?
-
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
ir
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
-
?
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
ir
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
ir
alpha-N-benzoyl-DL-arginine-beta-naphthylamide + H2O
alpha-N-benzoyl-DL-arginine + beta-naphthylamine
-
-
-
-
?
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
97% activity of substrate Leu-2-N-naphthylamine
-
ir
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
-
-
ir
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
-
-
ir
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
-
-
ir
Arg-2-naphthylamide + H2O
Arg + 2-naphthylamine
-
-
-
ir
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
ir
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
?
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
conventional test substrate
-
ir
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
ir
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
conventional test substrate
-
ir
Arg-7-amido-4-methylcoumarin + H2O
L-arginine + 7-amino-4-methylcoumarin
-
-
-
-
?
Arg-7-amido-4-methylcoumarin + H2O
L-arginine + 7-amino-4-methylcoumarin
-
assay at pH 5.5, 37°C
-
-
?
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
-
?
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
ir
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
ir
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
ir
benzoyl-DL-Arg-2-naphthylamide + H2O
benzoyl-DL-Arg + 2-naphthylamine
-
-
-
ir
benzoyl-L-Phe-L-Val-L-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
benzoyl-L-Phe-L-Val-L-Arg-4-methylcoumaryl-7-amide + H2O
benzoyl-L-Phe-L-Val-L-Arg + 7-amino-4-methylcoumarin
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
specific substrate
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
-
-
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
-
-
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
ir
Lys-Arg-(Met)enkephalin + H2O
Lys-Arg + (Met)enkephalin
-
-
-
-
?
Lys-Arg-(Met)enkephalin + H2O
Lys-Arg + (Met)enkephalin
-
-
-
-
?
Lys-Lys-(Met)enkephalin + H2O
Lys-Lys + (Met)enkephalin
-
-
-
-
?
Lys-Lys-(Met)enkephalin + H2O
Lys-Lys + (Met)enkephalin
-
-
-
-
?
Proteins + H2O
?
-
aminopeptidase and endopeptidase activity
-
-
?
Proteins + H2O
?
-
involved in tumor metastasis
-
-
?
Proteins + H2O
?
-
aminopeptidase and endopeptidase activity
-
-
?
Proteins + H2O
?
-
involved in processing of pre-proteins
-
-
?
Proteins + H2O
?
-
involved in human glioma, anaplastic astrocytoma, and glioblastoma progression and invasion
-
-
?
Proteins + H2O
?
-
involved in intracellular protein degradation
-
-
?
Proteins + H2O
?
-
aminopeptidase and endopeptidase activity
-
-
?
Proteins + H2O
?
-
-
-
-
?
Proteins + H2O
?
-
involved in cell growth, protein degradation, synthesis of peptide hormones and tumor metastasis
-
-
?
Proteins + H2O
?
-
involved in phagocytosis by macrophages
-
-
?
Proteins + H2O
?
-
rather broad specificity of aminopeptidase activity
-
-
?
Proteins + H2O
?
-
aminopeptidase and endopeptidase activity
-
-
?
Proteins + H2O
?
-
involved in processing of pre-proteins
-
-
?
additional information
?
-
-
activity as endopeptidase and aminopeptidase on synthetic substrates
-
-
?
additional information
?
-
-
enzyme is involved in maturation of the biologically active surfactant protein B
-
-
?
additional information
?
-
-
does not cleave benzyloxycarbonyl-Arg-Arg-7-amido-4-methylcoumarin, benzyloxycarbonyl-Leu-Arg-7-amido-4-methylcoumarin, and benzyloxycarbonyl-Phe-Arg-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
procathepsin H is not capable of autocleavage at pH 4.5-6.5
-
-
?
additional information
?
-
-
procathepsin H is not capable of autocleavage at pH 4.5-6.5
-
-
?
additional information
?
-
-
activity as endopeptidase and aminopeptidase on synthetic substrates
-
-
?
additional information
?
-
-
influence of Pro in position P1 to P3 on rate of peptide hydrolysis, P3 i.e. 3rd amino acid in N-terminal direction relative to point of cleavage, greatest increase in activity after substrate elongation to tetrapeptide
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2E)-1,3-diphenylprop-2-en-1-one
(2E)-2-(1,3-diphenylpropylidene)hydrazinecarboxamide
-
(2E)-2-[3-(2-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(2-methoxyphenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(3-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(3-methoxyphenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(3-nitrophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(4-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(4-methylphenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-2-[3-(4-nitrophenyl)-1-phenylpropylidene]hydrazinecarboxamide
-
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
(2S)-2-amino-N-[(1S)-2-(biphenyl-4-yl)-1-cyanoethyl]butanamide
-
-
(2Z)-2-(2-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, no activity remaining
(2Z)-2-(2-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, no activity remaining
(2Z)-2-(2-nitrobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 6.10% activity remaining
(2Z)-2-(3-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, no activity remaining
(2Z)-2-(3-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, no activity remaining
(2Z)-2-(4-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 20.80% activity remaining
(2Z)-2-(4-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 37.00% activity remaining
(2Z)-2-(4-nitrobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 25.40% activity remaining
(2Z)-2-benzylidenehydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 14.60% activity remaining
(2Z)-2-[(2E)-1,3-diphenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
-
(2Z)-2-[(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C, 1 mM, 13.5% activity remaining
1,3,5-triphenyl pyrazole
-
-
1,3,5-triphenyl-2-pyrazoline
-
-
1-[4-(2-methoxyphenyl)piperazin-1-yl]-3-[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]propan-2-ol
-
1H-spiro(cyclohexane-1,2-quinazolin)-4(3H)-one
-
competitive inhibition, 94.86% residual activity at 0.1 mM
2,5-diphenyl-1,3,4-oxadiazole
1 mM, 50.19% activity remaining
2-(2-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 25.12% activity remaining
2-(2-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 45.35% activity remaining
2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 92.07% activity remaining
2-(3-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 36.19% activity remaining
2-(3-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 48.08% activity remaining
2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 59.47% activity remaining
2-(4-(dimethylamino)phenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 88.37% residual activity at 0.1 mM
2-(4-bromophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 91.62% residual activity at 0.1 mM
2-(4-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 98.11% residual activity at 0.1 mM
2-(4-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 30.98% activity remaining
2-(4-fluorophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 94.05% residual activity at 0.1 mM
2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 95.94% residual activity at 0.1 mM
2-(4-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 43.49% activity remaining
2-(4-methylphenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 39.18% residual activity at 0.1 mM
2-(4-methylphenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 49.89% activity remaining
2-(4-nitrophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 81.89% residual activity at 0.1 mM
2-(4-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
1 mM, 69.33% activity remaining
2-benzyl-N'-methyl-N'-(pyridin-3-yl)but-3-ynehydrazide
-
2-chlorobenzohydrazide
-
non-competitive inhibition; non-competitive inhibition, 89.46% residual activity at 0.01 mM
2-methoxybenzohydrazide
-
non-competitive inhibition; non-competitive inhibition, 97.83% residual activity at 0.01 mM
2-phenyl-2,3-dihydroquinazolin-4(1H)-one
-
competitive inhibition, 79.73% residual activity at 0.1 mM
2-[[(2E)-2-(1,3-benzodioxol-5-ylmethylidene)hydrazinyl]carbonyl]-3-phenyl-1H-indole-5-sulfonamide
-
3,5-diphenyl-2-pyrazoline
-
-
3,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
3,5-diphenyl-4-amino-1,2,4-triazole
-
non-competitive inhibition; non-competitive inhibition, 69.73% residual activity at 0.01 mM
3-(2'-hydroxy-3'-methylphenyl)-5-(2'-hydroxy-3'-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 88.11% residual activity at 0.01 mM
3-(2'-methylphenyl)-5-(2'-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 82.97% residual activity at 0.01 mM
3-(2-chlorophenyl)-1-(4-bromophenyl)prop-2-en-1-one
-
3-(2-chlorophenyl)-1-(naphthalen-3-yl)prop-2-en-1-one
-
3-(2-chlorophenyl)-1-(pyridin-2-yl)prop-2-en-1-one
-
3-(2-chlorophenyl)-1-(thien-2-yl)prop-2-en-1-one
-
3-(2-hydroxy-3-methylphenyl)-5-(2-hydroxy-3-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(2-methylphenyl)-5-(2-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(3'-aminophenyl)-5-(3'-aminophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 16.37% residual activity at 0.01 mM
3-(3'-methylphenyl)-5-(3'-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 79.45% residual activity at 0.01 mM
3-(3'-nitrophenyl)-5-(3'-nitrophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 45.13% residual activity at 0.01 mM
3-(3-aminophenyl)-5-(3-aminophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(3-chlorophenyl)-1-(4-aminophenyl)prop-2-en-1-one
-
3-(3-chlorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one
-
3-(3-chlorophenyl)-1-(4-hydroxyphenyl)-prop-2-en-1-one
-
3-(3-chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one
-
3-(3-methylphenyl)-5-(3-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(4'-chlorophenyl)-5-(4'-chlorophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 24.35% residual activity at 0.01 mM
3-(4'-methylphenyl)-5-(4'-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 89.46% residual activity at 0.01 mM
3-(4-chlorophenyl)-1-(4-(N'-4-nitrophenyl)methylene)aminophenyl)prop-2-en-1-one
-
3-(4-chlorophenyl)-1-(4-methylphenyl)prop-2-en-1-one
-
3-(4-chlorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one
-
3-(4-chlorophenyl)-5-(4-chlorophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-(4-methylphenyl)-5-(4-methylphenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-phenyl-5-(3-nitrophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
3-phenyl-5-(4'-nitrophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition, 78.11% residual activity at 0.01 mM
3-phenyl-5-(4-nitrophenyl)-4-amino-1,2,4-triazole
-
non-competitive inhibition
4-aminophenylmercuric acetate
-
93% inhibition at 1 mM
4-bromo-N-[(2-methylimidazo[1,2-a]pyridin-3-yl)carbonyl]benzenecarbohydrazonoyl chloride
-
4-bromochalcone phenyl hydrazone
-
-
4-chlorochalcone phenyl hydrazone
-
-
4-hydroxybenzohydrazide
-
non-competitive inhibition; non-competitive inhibition, 91.62% residual activity at 0.01 mM
4-methoxybenzohydrazide
-
non-competitive inhibition; non-competitive inhibition, 45% residual activity at 0.01 mM
4-methoxychalcone phenyl hydrazone
-
-
4-methylchalcone phenyl hydrazone
-
-
4-nitrochalcone phenyl hydrazone
-
-
5,5'-dithiobis(2-nitrobenzoic acid)
-
95% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(2-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(3-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(3-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(4-bromophenyl)-1,3-diphenyl pyrazole
-
-
5-(4-bromophenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-bromophenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-chlorophenyl)-1,3-diphenyl pyrazole
-
-
5-(4-chlorophenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-chlorophenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(4-methoxyphenyl)-1,3-diphenyl pyrazole
-
-
5-(4-methoxyphenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(4-methylphenyl)-1,3-diphenyl pyrazole
-
-
5-(4-methylphenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-methylphenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
5-(4-nitrophenyl)-1,3-diphenyl pyrazole
-
-
5-(4-nitrophenyl)-1,3-diphenyl-2-pyrazoline
-
-
5-(4-nitrophenyl)-3-phenyl-2-pyrazoline
-
-
5-(4-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
-
acetyl-(Ala)2-Pro-Ala-CH2Cl
-
100% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
acetyl-(Ala)2-Pro-Val-CH2Cl
-
100% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
acetyl-(Ala)4-CH2Cl
-
100% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
alpha-2-Macroglobulin
-
-
-
benzyloxycarbonyl-Gly-Leu-NH
-
inhibits processing of proenzyme to active form
Benzyloxycarbonyl-Leu-NH2
-
inhibits formation of active enzyme from procathepsin H
Benzyloxycarbonyl-Phe-Phe-CHN2
-
31% inhibition at 0.01 mM
bestatin
-
62% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
CdCl2
-
90% inhibition at 1 mM
chalcone phenyl hydrazone
-
-
chicken egg white cystatin
-
-
-
chymostatin B
-
47% inhibition at 0.016 mM
-
CNWAAGYNCGGGS-NH2
-
cyclic peptide with intramolecular disulfide bond, comparison of inhibitory effect with cathepsin K, cathepsin L, cathepsin B and papain
CNWTLGGYKCGGGS-NH2
-
cyclic peptide with intramolecular disulfide bond, comparison of inhibitory effect with cathepsin K, cathepsin L, cathepsin B and papain
CoCl2
-
100% inhibition at 1 mM
CPI-H
-
peptide inhibitor of 13 kDa from rabbit skeletal muscle, noncompetitive
-
CPI-L
-
peptide inhibitor of 23 kDa from rabbit skeletal muscle, noncompetitive
-
CuCl2
-
94% inhibition at 1 mM
CWEWGGWHCGGSS-OH
-
cyclic peptide with intramolecular disulfide bond, comparison of inhibitory effect with cathepsin K, cathepsin L, cathepsin B and papain
CWSMMGFQCGGGS-NH2
-
cyclic peptide with intramolecular disulfide bond, comparison of inhibitory effect with cathepsin K, cathepsin L, cathepsin B and papain
cystatin C, full-length
-
-
-
cystatin C, truncated form
-
deletion of 10 N-terminal amino acids
-
decyl bromide
-
100% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
DTNB
-
100% inhibition at 1 mM
E-64
-
irreversible active site inhibitor
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
Human cystatin C
-
Ki: 0.01-0.03 nM
-
Hyamine 1622
-
52% inhibition at 1 mM
Leu-CH2-Cl
-
complete inhibition at 0.01 mM
MnSO4
-
64% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
N'-(4-[(E)-[2-(2-formylphenyl)hydrazinylidene]methyl]phenyl)-N-phenylimidoformamide
-
N-(3-methoxypyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
-
N-acetyl-3,5-diphenyl pyrazolines
-
-
N-acetyl-5-(4-bromophenyl)-3-phenyl-2-pyrazoline
-
-
N-acetyl-5-(4-chlorophenyl)-3-phenyl-2-pyrazoline
-
-
N-acetyl-5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline
-
-
N-acetyl-5-(4-methylphenyl)-3-phenyl-2-pyrazoline
-
-
N-acetyl-5-(4-nitrophenyl)-3-phenyl-2-pyrazoline
-
-
N-benzoyl-3,5-diphenylpyrazoline
-
66.19% residual activity at 0.01 mM
N-benzoyl-5-(2-chloro phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
55.13% residual activity at 0.01 mM
N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
79.37% residual activity at 0.01 mM
N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
34.77% residual activity at 0.01 mM
N-benzoyl-5-(3-chloro phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
44.2% residual activity at 0.01 mM
N-benzoyl-5-(3-methoxy phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
76.06% residual activity at 0.01 mM
N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
27.49% residual activity at 0.01 mM
N-benzoyl-5-(4-chloro phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
62.47% residual activity at 0.01 mM
N-benzoyl-5-(4-methoxy phenyl)-3-phenylpyrazoline
-
-
N-benzoyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
69.69% residual activity at 0.01 mM
N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
28.77% residual activity at 0.01 mM
N-benzyl-5-hydroxy-1-methyl-2-[2-[(1,3,4-oxadiazol-2-ylcarbonyl)amino]propan-2-yl]-6-oxo-1,6-dihydropyrimidine-4-carboxamide
-
N-formyl-3,5-diphenylpyrazoline
-
76.78% residual activity at 10 mM
N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
61.38% residual activity at 10 mM
N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
92.97% residual activity at 0.001 mM
N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
30.2% residual activity at 0.001 mM
N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
49.57% residual activity at 0.001 mM
N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
86.03% residual activity at 0.001 mM
N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
14.15% residual activity at 0.001 mM
N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
69.38% residual activity at 0.001 mM
N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
80.06% residual activity at 0.001 mM
N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
27.64% residual activity at 0.001 mM
N-[(1E,2S)-1-(2-benzoylhydrazinylidene)-4-phenylbutan-2-yl]-N2-(piperidin-1-ylcarbonyl)-L-leucinamide
-
N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-norvalinamide
-
-
N-[(5S,8S,11S,13Z,19S)-8-(4-fluorobenzyl)-5-formyl-2,7,10-trioxo-18-oxa-1,6,9-triazabicyclo[17.2.1]docos-13-en-11-yl]-5-methyl-1,2-oxazole-3-carboxamide
-
N-[(E)-(phenylimino)methyl]benzamide
1 mM, 69.90% activity remaining
N-[(E)-[(2-chlorophenyl)imino]methyl]benzamide
1 mM, 25.66% activity remaining
N-[(E)-[(2-methoxyphenyl)imino]methyl]benzamide
1 mM, 41.11% activity remaining
N-[(E)-[(2-nitrophenyl)imino]methyl]benzamide
1 mM, 90.07% activity remaining
N-[(E)-[(3-chlorophenyl)imino]methyl]benzamide
1 mM, 39.45% activity remaining
N-[(E)-[(3-methoxyphenyl)imino]methyl]benzamide
1 mM, 49.59% activity remaining
N-[(E)-[(3-nitrophenyl)imino]methyl]benzamide
1 mM, 73.01% activity remaining
N-[(E)-[(4-chlorophenyl)imino]methyl]benzamide
1 mM, 24.75% activity remaining
N-[(E)-[(4-methoxyphenyl)imino]methyl]benzamide
1 mM, 40.2% activity remaining
N-[(E)-[(4-methylphenyl)imino]methyl]benzamide
1 mM, 39.93% activity remaining
N-[(E)-[(4-nitrophenyl)imino]methyl]benzamide
1 mM, 75.07% activity remaining
N-[2-(4-methoxyphenyl)ethyl]-2-(2-phenoxyphenyl)acetamide
-
N2-(morpholin-4-ylcarbonyl)-N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-leucinamide
-
-
p-Hydroxymercuriphenylsulfonic acid
-
83% inhibition at 0.011 mM, substrate Leu-2-N-naphthylamine
PCMB
-
46% inhibition at 1 mM
phenylacetyl hydrazine
-
non-competitive inhibition; non-competitive inhibition, 81.08% residual activity at 0.01 mM
Soybean trypsin inhibitor
-
Thiol proteinase inhibitor
-
Zn(CH3COO)2
-
85% inhibition at 1 mM
ZnSO4
-
87% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
(2E)-1,3-diphenylprop-2-en-1-one
-
(2E)-1,3-diphenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 93.50% activity remaining
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 42.00% activity remaining
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 66.00% activity remaining
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 0.30% activity remaining
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 51.40% activity remaining
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 55.20% activity remaining
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 73.30% activity remaining
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 55.60% activity remaining
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 92.50% activity remaining
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
-
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 61.80% activity remaining
1,10-phenanthroline
-
4% inhibition at 5 mM
1,10-phenanthroline
-
inhibits processing of proenzyme to active form
2,2'-dipyridyl disulfide
-
thiol-specific two-protonic-state reactivity probe
2,2'-dipyridyl disulfide
-
96% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
antipain
-
53% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
antipain
-
91% inhibition at 0.1 mM
antipain
-
at 0.1 mM, 95% inhibition
chicken cystatin
-
Ki: 0.1 nM
-
cystatin
-
-
-
cystatin C
-
-
-
cystatin C
physiological inhibitor of cathepsin H
-
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
90% inhibition at 0.001 mM, substrate Leu-2-N-naphthylamine
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
100% inhibition at 0.1 mM
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
E-64-d, inhibits processing of proenzyme to synthetic analogs
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
-
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
E-64-d, inhibits processing of proenzyme to active form
ethyl(2S,3S)-3-(S)-3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl oxirane-2-carboxylate
-
65-76% inhibition at 0.01 mg/ml, isoform-dependent
HgCl2
-
100% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
HgCl2
-
73% inhibition at 1 mM
human stefin A
-
Ki: 0.1-0.16 nM
-
human stefin B
-
Ki: 0.003 nM
-
iodoacetamide
-
91% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
iodoacetamide
-
99% inhibition at 1 mM
iodoacetic acid
-
100% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
iodoacetic acid
-
99% inhibition at 1 mM
iodoacetic acid
-
at 1 mM, 99% inhibition
iodoacetic acid
-
71-77% inhibition at 0.5 mM, isoenzyme-dependent
Leu-CH2Cl
-
92% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
Leu-CH2Cl
-
85% inhibition at 0.001 mM
leupeptin
-
100% inhibition at 0.1 mM, substrate Leu-2-N-naphthylamine
leupeptin
-
complete inhibition at 0.01 mM
leupeptin
-
80% inhibition at 0.1 mM
leupeptin
-
low sensitivity
leupeptin
-
29% inhibition at 0.021 mM
leupeptin
-
at 0.1 mM, 99% inhibition
leupeptin
-
Ki: 0.005 mM; low sensitivity
leupeptin
-
inhibits processing of proenzyme to active form
N-ethylmaleimide
-
98% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
N-ethylmaleimide
-
69% inhibition at 1 mM
Proteinase inhibitor
-
rat liver
-
Proteinase inhibitor
-
from rabbit lung
-
puromycin
-
20% inhibition at 1 mM, substrate Leu-2-N-naphthylamine
puromycin
-
36% inhibition at 1 mM
Soybean trypsin inhibitor
-
8% inhibition at 0.005 mM
-
Soybean trypsin inhibitor
-
non-specific
-
Thiol proteinase inhibitor
-
from human serum, human lung, molecular weights: 13000 and 80000, the latter including haptoglobin, 4-7% inhibition
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
Thiol proteinase inhibitor
-
proteinase inhibitor from rat, man, hog, Tetrahymena, tuna, chicken, toad, purified rat lung inhibitors have molecular weight of 14000, purified hog kidney inhibitors have molecular weight of 11000, also high molecular weight inhibitors in human and rat serum, tissue distributions in humans and rat: inhibitors widely distributed, probaly regulatory function
-
thiol-blocking agents
-
-
thiol-blocking agents
-
-
thiol-blocking agents
-
-
tosyl-Leu-CH2Cl
-
63% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
tosyl-Leu-CH2Cl
-
89% inhibition at 1 mM
tosyl-Leu-CH2Cl
-
60% inhibition at 0.01 mM
tosyl-Leu-CH2Cl
-
17-35% inhibition at 0.1 mM, isoenzyme-dependent
tosyl-Phe-CH2Cl
-
69% inhibition at 0.01 mM, substrate Leu-2-N-naphthylamine
tosyl-Phe-CH2Cl
-
84%inhibition at 1 mM
tosyl-Phe-CH2Cl
-
79% inhibition at 0.01 mM
additional information
-
amastatin, arphamenine A, and bestatin have no effect on cathepsin H
-
additional information
2,5-diaryloxadiazoles and their precursors as inhibitors of cathepsins B, H and L, synthesis and inhibitory potencies, pharmacological evaluation, molecular docking, overview. Structure-activity relationship studies show that 2,5-diaryloxadiazoles are less inhibitory than their precursors, N-subsituted benzylidenebenzohydrazides. Cathepsin H activity is maximally inhibited by (2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one and (2Z)-2-[(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide, assay with liver hommogenate. All compounds exhibited a competitive type of inhibition
-
additional information
chalcones, semicarbazones and pyrazolines as inhibitors of cathepsins H, synthesis and inhibitory potencies, pharmacological evaluation, molecular docking, overview. Structure-activity relationship analysis
-
additional information
semicarbazones and thiosemicarbazones as inhibitors of cathepsins H, active site docking study and structure-activity relationship analysis, comparison to cathepsin L, overview
-
additional information
synthesis of a small library of chalcones and study of their role as inhibitors of cathepsins, overview. The most potent inhibitors among all compounds are chloro-substituted compounds for cathepsin H. Docking analysis and modeling, overview
-
additional information
no significant inhibitory effect of enzyme propeptide fragments, detailed analysis using several different peptides. Recombinant enzyme lacking the mini-chain shows inhibitory interaction
-
additional information
molecular basis for the inhibition of the mature enzyme by the prodomain. The prodomain of procathepsin H has an N-terminal helical subdomain (Ala1P-Ser75P) and an extended portion (Glu76P-Pro93P) that links the helical subdomain to Tyr1 of the mature domain
-
additional information
-
molecular basis for the inhibition of the mature enzyme by the prodomain. The prodomain of procathepsin H has an N-terminal helical subdomain (Ala1P-Ser75P) and an extended portion (Glu76P-Pro93P) that links the helical subdomain to Tyr1 of the mature domain
-
additional information
-
amastatin, arphamenine A, and bestatin have no effect on cathepsin H
-
additional information
-
not inhibitory: pepstatin, bestatin, puromycin, phenylmethylsulfonylfluoride, trypsin inhibitor
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Altered expression of genes involved in the production and degradation of endometrial extracellular matrix in patients with unexplained infertility and recurrent miscarriages.
Alveolitis, Extrinsic Allergic
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Alzheimer Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Arthritis
Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases.
Arthritis, Rheumatoid
Determination of cathepsins B and H in sera and synovial fluids of patients with different joint diseases.
Astrocytoma
Expression and the role of cathepsin H in human glioma progression and invasion.
Atherosclerosis
Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early atherogenesis.
Brain Neoplasms
Some physicochemical properties of cathepsin H from human meningioma.
Brain Neoplasms
[Cathepsin H activity in the human brain and human brain neoplasms]
Breast Neoplasms
Cathepsins B, H and L in human breast carcinoma.
Carcinogenesis
Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.
Carcinogenesis
[Changes in active cysteine cathepsins in lysosomes from tissues thyroid papillary carcinomas with various biological characteristics].
Carcinoma
Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas.
Carcinoma
Analysis of a truncated form of cathepsin H in human prostate tumor cells.
Carcinoma
Cathepsin H expression distinguishes oncocytomas from renal cell carcinomas.
Carcinoma
Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma.
Carcinoma, Hepatocellular
Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells.
Carcinoma, Papillary
[Changes in active cysteine cathepsins in lysosomes from tissues thyroid papillary carcinomas with various biological characteristics].
Carcinoma, Renal Cell
Cathepsin H expression distinguishes oncocytomas from renal cell carcinomas.
Carcinosarcoma
Molecular cloning of rat precursor cathepsin H and the expression of five lysosomal cathepsins in normal tissues and in a rat carcinosarcoma.
cathepsin h deficiency
Cathepsin H deficiency decreases hypoxia-ischemia-induced hippocampal atrophy in neonatal mice through attenuated TLR3/IFN-? signaling.
cathepsin h deficiency
Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade.
Cholesteatoma
Gene expression analysis of human middle ear cholesteatoma using complementary DNA arrays.
Colorectal Neoplasms
Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas.
Colorectal Neoplasms
Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
Cryptogenic Organizing Pneumonia
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Diabetes Mellitus, Type 1
Genetic and environmental factors regulate the type 1 diabetes gene CTSH via differential DNA methylation.
Encephalomyelitis
Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade.
Encephalomyelitis, Autoimmune, Experimental
Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade.
Epstein-Barr Virus Infections
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors.
Gallbladder Neoplasms
Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics.
Glioblastoma
Expression and the role of cathepsin H in human glioma progression and invasion.
Glioma
Expression and the role of cathepsin H in human glioma progression and invasion.
Huntington Disease
Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease.
Idiopathic Pulmonary Fibrosis
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Infections
Channel catfish, Ictalurus punctatus, cysteine proteinases: cloning, characterisation and expression of cathepsin H and L.
Infections
Diagnosis of Fasciola gigantica infection using a monoclonal antibody-based sandwich ELISA for detection of circulating cathepsin B3 protease.
Infections
The combined recombinant cathepsin L1H and cathepsin B3 vaccine against Fasciola gigantica infection.
Infections
Vaccine potential of recombinant cathepsin B against Fasciola gigantica.
Infertility
Altered expression of genes involved in the production and degradation of endometrial extracellular matrix in patients with unexplained infertility and recurrent miscarriages.
Inflammatory Breast Neoplasms
Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer.
Insulinoma
Immunocytochemical localization of cathepsins B and H in human pancreatic endocrine cells and insulinoma cells.
Lung Neoplasms
Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking.
Lung Neoplasms
[Serum activity of chitotriosidase, lysozyme and cathepsin H in patients with lung cancer and patients with inflammatory exudate (preliminary report)]
Melanoma
Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Melanoma
Enzyme-linked immunosorbent assay for the detection of total cathepsin H in human tissue cytosols and sera.
Melanoma
Generation of a double binary transgenic zebrafish model to study myeloid gene regulation in response to oncogene activation in melanocytes.
Melanoma, Amelanotic
Cathepsin B-like activity in viable tumor cells isolated from rodent tumors.
Melanoma, Experimental
Cathepsin B: association with plasma membrane in metastatic tumors.
Meningioma
Some physicochemical properties of cathepsin H from human meningioma.
Mouth Neoplasms
[Activity of cathepsin H in blood and biopsies of patients with precancerous conditions and mouth cancer]
Multiple Sclerosis
Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade.
Narcolepsy
Genetic association, seasonal infections and autoimmune basis of narcolepsy.
Narcolepsy
ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy.
Narcolepsy
The autoimmune basis of narcolepsy.
Neoplasm Metastasis
Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.
Neoplasms
Alterations in cathepsin H activity and protein patterns in human colorectal carcinomas.
Neoplasms
Analysis of a truncated form of cathepsin H in human prostate tumor cells.
Neoplasms
Cathepsin B activity in human lung tumor cell lines: ultrastructural localization, pH sensitivity, and inhibitor status at the cellular level.
Neoplasms
Cathepsin B-like activity in viable tumor cells isolated from rodent tumors.
Neoplasms
Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.
Neoplasms
Cathepsin H regulated by the thyroid hormone receptors associate with tumor invasion in human hepatoma cells.
Neoplasms
Cathepsins B, H and L in human breast carcinoma.
Neoplasms
Cathepsins in basal cell carcinomas: activity, immunoreactivity and mRNA staining of cathepsins B, D, H and L.
Neoplasms
Cysteine proteases and cell differentiation: excystment of the ciliated protist Sterkiella histriomuscorum.
Neoplasms
Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking.
Neoplasms
Deletion of cathepsin H perturbs angiogenic switching, vascularization and growth of tumors in a mouse model of pancreatic islet cell cancer.
Neoplasms
Design, synthesis and docking studies of bischalcones based quinazoline-2(1H)-ones and quinazoline-2(1H)-thiones derivatives as novel inhibitors of cathepsin B and cathepsin H.
Neoplasms
Expression and the role of cathepsin H in human glioma progression and invasion.
Neoplasms
IFN-gamma increases cathepsin H mRNA levels in mouse macrophages.
Neoplasms
ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy.
Neoplasms
Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands of male NOD mouse.
Neoplasms
Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer.
Neoplasms
Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma.
Neoplasms
Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer.
Neoplasms
Some physicochemical properties of cathepsin H from human meningioma.
Neoplasms
The role of peptidases in cancer of the rectum and sigmoid colon.
Neoplasms
Use of a transgenic mouse model to identify markers of human lung tumors.
Neoplasms
[Activity of cathepsin H in blood and biopsies of patients with precancerous conditions and mouth cancer]
Neoplasms
[Cathepsin H activity in the human brain and human brain neoplasms]
Neoplasms
[Changes in active cysteine cathepsins in lysosomes from tissues thyroid papillary carcinomas with various biological characteristics].
Neoplasms
[Cysteine cathepsins secreted into the blood as markers of tumor growth]
Neuroinflammatory Diseases
The induction of neuronal death by up-regulated microglial cathepsin H in LPS-induced neuroinflammation.
Osteoradionecrosis
[Cysteine cathepsins secreted into the blood as markers of tumor growth]
Osteosarcoma
Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.
Pancreatic Neoplasms
Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization.
Pneumonia
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Polycystic Kidney, Autosomal Dominant
Functional defects in lysosomal enzymes in autosomal dominant polycystic kidney disease (ADPKD): abnormalities in synthesis, molecular processing, polarity, and secretion.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases.
Precancerous Conditions
[Activity of cathepsin H in blood and biopsies of patients with precancerous conditions and mouth cancer]
Prostatic Intraepithelial Neoplasia
Analysis of a truncated form of cathepsin H in human prostate tumor cells.
Prostatic Neoplasms
Cathepsin H indirectly regulates morphogenetic protein-4 (BMP-4) in various human cell lines.
Prostatic Neoplasms
Cathepsin H mediates the processing of talin and regulates migration of prostate cancer cells.
Pulmonary Alveolar Proteinosis
Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis.
Pulmonary Eosinophilia
The significance of cathepsins, thrombin and aminopeptidase in diffuse interstitial lung diseases.
Thymoma
A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis.
Thyroid Neoplasms
Favorable Prognostic Impact of Cathepsin H (CTSH) High Expression in Thyroid Carcinoma.
Tuberculosis
Investigating potential transmission of antimicrobial resistance in an open-plan hospital ward: a cross-sectional metagenomic study of resistome dispersion in a lower middle-income setting.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.263 - 8.19
(2E)-1,3-diphenylprop-2-en-1-one
0.066
(2E)-2-(1,3-diphenylpropylidene)hydrazinecarboxamide
pH 6.0, 37°C
0.033
(2E)-2-[3-(2-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.054
(2E)-2-[3-(2-methoxyphenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.06
(2E)-2-[3-(3-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.066
(2E)-2-[3-(3-methoxyphenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.033
(2E)-2-[3-(3-nitrophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.021
(2E)-2-[3-(4-chlorophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.04
(2E)-2-[3-(4-methylphenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.032
(2E)-2-[3-(4-nitrophenyl)-1-phenylpropylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.11 - 0.43
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
0.1 - 1.08
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
0.027 - 0.312
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
0.11 - 0.63
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
0.06 - 0.7
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
0.083 - 1.66
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
0.138 - 0.71
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
0.151 - 7.04
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
0.1 - 1
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
0.0037
(2S)-2-amino-N-[(1S)-2-(biphenyl-4-yl)-1-cyanoethyl]butanamide
-
-
0.208
(2Z)-2-(2-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, no activity remaining
0.28
(2Z)-2-(2-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, no activity remaining
0.009
(2Z)-2-(2-nitrobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 6.10% activity remaining
0.704
(2Z)-2-(3-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, no activity remaining
0.016
(2Z)-2-(3-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, no activity remaining
0.17
(2Z)-2-(4-chlorobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 20.80% activity remaining
0.35
(2Z)-2-(4-methoxybenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 37.00% activity remaining
0.2
(2Z)-2-(4-nitrobenzylidene)hydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 25.40% activity remaining
0.06
(2Z)-2-benzylidenehydrazinecarbothioamide
pH 6.0, 37°C, 1 mM, 14.60% activity remaining
0.1
(2Z)-2-[(2E)-1,3-diphenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.043
(2Z)-2-[(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.066
(2Z)-2-[(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.096
(2Z)-2-[(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.074
(2Z)-2-[(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.023
(2Z)-2-[(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.029
(2Z)-2-[(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.054
(2Z)-2-[(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.045
(2Z)-2-[(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C
0.025
(2Z)-2-[(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-ylidene]hydrazinecarboxamide
pH 6.0, 37°C, 1 mM, 13.50% activity remaining
0.01859
1,3,5-triphenyl pyrazole
-
pH 7, 37°C
0.005388
1,3,5-triphenyl-2-pyrazoline
-
pH 7, 37°C
0.09009
1H-spiro(cyclohexane-1,2-quinazolin)-4(3H)-one
-
at pH 7.0 and 37°C
0.00272
2,5-diphenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.00056
2-(2-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.00147
2-(2-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.00669
2-(2-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.00113
2-(3-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.00161
2-(3-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.00385
2-(3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.01858
2-(4-(dimethylamino)phenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37°C
0.05263
2-(4-bromophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37°C
0.02325
2-(4-chlorophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37°C
0.001
2-(4-chlorophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.00818
2-(4-fluorophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37°C
0.05682
2-(4-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37°C
0.00133
2-(4-methoxyphenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.0025
2-(4-methylphenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37°C
0.00255
2-(4-methylphenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.01042
2-(4-nitrophenyl)-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37°C
0.00496
2-(4-nitrophenyl)-5-phenyl-1,3,4-oxadiazole
pH 5.0, 37°C
0.0901
2-chlorobenzohydrazide
0.588
2-methoxybenzohydrazide
0.01441
2-phenyl-2,3-dihydroquinazolin-4(1H)-one
-
at pH 7.0 and 37°C
0.006024
3,5-diphenyl-2-pyrazoline
-
pH 7, 37°C
0.192
3,5-diphenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.0232
3,5-diphenyl-4-amino-1,2,4-triazole
0.0781
3-(2'-hydroxy-3'-methylphenyl)-5-(2'-hydroxy-3'-methylphenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.0532
3-(2'-methylphenyl)-5-(2'-methylphenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.0214
3-(2-chlorophenyl)-1-(4-bromophenyl)prop-2-en-1-one
pH 5.0, 37°C
0.0989
3-(2-chlorophenyl)-1-(naphthalen-3-yl)prop-2-en-1-one
pH 5.0, 37°C
0.0472
3-(2-chlorophenyl)-1-(pyridin-2-yl)prop-2-en-1-one
pH 5.0, 37°C
0.217
3-(2-chlorophenyl)-1-(thien-2-yl)prop-2-en-1-one
pH 5.0, 37°C
0.0781
3-(2-hydroxy-3-methylphenyl)-5-(2-hydroxy-3-methylphenyl)-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.0532
3-(2-methylphenyl)-5-(2-methylphenyl)-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.002
3-(3'-aminophenyl)-5-(3'-aminophenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.0387
3-(3'-methylphenyl)-5-(3'-methylphenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.0086
3-(3'-nitrophenyl)-5-(3'-nitrophenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.002
3-(3-aminophenyl)-5-(3-aminophenyl)-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.128
3-(3-chlorophenyl)-1-(4-aminophenyl)prop-2-en-1-one
pH 5.0, 37°C
0.0317
3-(3-chlorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one
pH 5.0, 37°C
0.163
3-(3-chlorophenyl)-1-(4-hydroxyphenyl)-prop-2-en-1-one
pH 5.0, 37°C
0.298
3-(3-chlorophenyl)-1-(furan-2-yl)prop-2-en-1-one
pH 5.0, 37°C
0.0387
3-(3-methylphenyl)-5-(3-methylphenyl)-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.0033
3-(4'-chlorophenyl)-5-(4'-chlorophenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.0901
3-(4'-methylphenyl)-5-(4'-methylphenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.0133
3-(4-chlorophenyl)-1-(4-(N'-4-nitrophenyl)methylene)aminophenyl)prop-2-en-1-one
pH 5.0, 37°C
0.0416
3-(4-chlorophenyl)-1-(4-methylphenyl)prop-2-en-1-one
pH 5.0, 37°C
0.405
3-(4-chlorophenyl)-1-(4-nitrophenyl)prop-2-en-1-one
pH 5.0, 37°C
0.0033
3-(4-chlorophenyl)-5-(4-chlorophenyl)-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.0901
3-(4-methylphenyl)-5-(4-methylphenyl)-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.0086
3-phenyl-5-(3-nitrophenyl)-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.0364
3-phenyl-5-(4'-nitrophenyl)-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.0364
3-phenyl-5-(4-nitrophenyl)-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.0026
4-bromochalcone phenyl hydrazone
-
pH 7, 37°C
0.0011
4-chlorochalcone phenyl hydrazone
-
pH 7, 37°C
0.1123
4-hydroxybenzohydrazide
0.0082
4-methoxybenzohydrazide
0.001695
4-methoxychalcone phenyl hydrazone
-
pH 7, 37°C
0.0029
4-methylchalcone phenyl hydrazone
-
pH 7, 37°C
0.001905
4-nitrochalcone phenyl hydrazone
-
pH 7, 37°C
0.06
5-(2-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.04
5-(2-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.025
5-(3-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.043
5-(3-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.038
5-(3-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.0038
5-(4-bromophenyl)-1,3-diphenyl pyrazole
-
pH 7, 37°C
0.002907
5-(4-bromophenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37°C
0.00537
5-(4-bromophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.002346
5-(4-chlorophenyl)-1,3-diphenyl pyrazole
-
pH 7, 37°C
0.001174
5-(4-chlorophenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37°C
0.001568
5-(4-chlorophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.066
5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.0033
5-(4-methoxyphenyl)-1,3-diphenyl pyrazole
-
pH 7, 37°C
0.002119
5-(4-methoxyphenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37°C
0.0098
5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.048
5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.007396
5-(4-methylphenyl)-1,3-diphenyl pyrazole
-
pH 7, 37°C
0.004184
5-(4-methylphenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37°C
0.0082
5-(4-methylphenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.048
5-(4-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.00257
5-(4-nitrophenyl)-1,3-diphenyl pyrazole
-
pH 7, 37°C
0.003158
5-(4-nitrophenyl)-1,3-diphenyl-2-pyrazoline
-
pH 7, 37°C
0.0033
5-(4-nitrophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.06
5-(4-nitrophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamide
pH 6.0, 37°C
0.00000052
bovine stefin B
-
pH 6.5, 25°C, native enzyme
-
0.0048
chalcone phenyl hydrazone
-
pH 7, 37°C
0.000000049
chicken cystatin
-
pH 6.5, 25°C, mutant lacking the mini chain
-
0.000000095 - 0.00000053
chicken egg white cystatin
-
0.0179
CNWAAGYNCGGGS-NH2
-
pH 6.8, 22°C
0.0051
CNWTLGGYKCGGGS-NH2
-
pH 6.8, 22°C
0.00000033
CPI-H
-
pH 6.2, 30°C
-
0.0000005
CPI-L
-
pH 6.2, 30°C
-
0.0049
CWEWGGWHCGGSS-OH
-
pH 6.8, 22°C
0.0039
CWSMMGFQCGGGS-NH2
-
pH 6.8, 22°C
0.000000071
cystatin C, full-length
-
25°C, pH 7.0
-
0.00000032
cystatin C, truncated form
-
25°C, pH 7.0
-
0.000000099
human stefin A
-
pH 6.5, 25°C, mutant lacking the mini chain
-
0.000000074
human stefin B
-
pH 6.5, 25°C, mutant lacking the mini chain
-
0.01767
N-acetyl-3,5-diphenyl pyrazolines
-
pH 7, 37°C
0.01266
N-acetyl-5-(4-bromophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.01
N-acetyl-5-(4-chlorophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.14
N-acetyl-5-(4-methoxyphenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.03546
N-acetyl-5-(4-methylphenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.02432
N-acetyl-5-(4-nitrophenyl)-3-phenyl-2-pyrazoline
-
pH 7, 37°C
0.0032
N-benzoyl-3,5-diphenylpyrazoline
0.00189
N-benzoyl-5-(2-chloro phenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00189
N-benzoyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00965
N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
0.00144
N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline
0.00181
N-benzoyl-5-(3-chloro phenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00181
N-benzoyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00503
N-benzoyl-5-(3-methoxy phenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00503
N-benzoyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00098
N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline
0.00301
N-benzoyl-5-(4-chloro phenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00301
N-benzoyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.0041
N-benzoyl-5-(4-methoxy phenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.0041
N-benzoyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00127
N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline
0.000174
N-formyl-3,5-diphenylpyrazoline
0.000135
N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline
0.000387
N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
0.0000963
N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline
0.00013
N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline
0.000272
N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
0.0000519
N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline
0.000137
N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline
0.000221
N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
0.000058
N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline
0.00014
N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-norvalinamide
-
-
0.00214
N-[(E)-(phenylimino)methyl]benzamide
pH 5.0, 37°C
0.00068
N-[(E)-[(2-chlorophenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.0014
N-[(E)-[(2-methoxyphenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.00484
N-[(E)-[(2-nitrophenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.00113
N-[(E)-[(3-chlorophenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.00168
N-[(E)-[(3-methoxyphenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.00364
N-[(E)-[(3-nitrophenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.00044
N-[(E)-[(4-chlorophenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.00133
N-[(E)-[(4-methoxyphenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.00126
N-[(E)-[(4-methylphenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.00416
N-[(E)-[(4-nitrophenyl)imino]methyl]benzamide
pH 5.0, 37°C
0.0014
N2-(morpholin-4-ylcarbonyl)-N-[(1E,3S)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl]-L-leucinamide
-
-
0.0425
phenylacetyl hydrazine
0.263
(2E)-1,3-diphenylprop-2-en-1-one
pH 6.0, 37°C
8.19
(2E)-1,3-diphenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 93.50% activity remaining
0.11
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
0.43
(2E)-3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 42.00% activity remaining
0.1
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
1.08
(2E)-3-(2-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 66.00% activity remaining
0.027
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 0.30% activity remaining
0.312
(2E)-3-(3-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
0.11
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
0.63
(2E)-3-(3-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 51.40% activity remaining
0.06
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
0.7
(2E)-3-(3-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 55.20% activity remaining
0.083
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
1.66
(2E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 73.30% activity remaining
0.138
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
0.71
(2E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 55.60% activity remaining
0.151
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
7.04
(2E)-3-(4-methylphenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 92.50% activity remaining
0.1
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C
1
(2E)-3-(4-nitrophenyl)-1-phenylprop-2-en-1-one
pH 6.0, 37°C, 1 mM, 61.80% activity remaining
0.0901
2-chlorobenzohydrazide
-
at pH 7.0 and 37°C
0.0901
2-chlorobenzohydrazide
-
pH 5, 37°C
0.588
2-methoxybenzohydrazide
-
at pH 7.0 and 37°C
0.588
2-methoxybenzohydrazide
-
pH 5, 37°C
0.0232
3,5-diphenyl-4-amino-1,2,4-triazole
-
at pH 7.0 and 37°C
0.0232
3,5-diphenyl-4-amino-1,2,4-triazole
-
pH 5, 37°C
0.1123
4-hydroxybenzohydrazide
-
at pH 7.0 and 37°C
0.1123
4-hydroxybenzohydrazide
-
pH 5, 37°C
0.0082
4-methoxybenzohydrazide
-
at pH 7.0 and 37°C
0.0082
4-methoxybenzohydrazide
-
pH 5, 37°C
0.000000095
chicken egg white cystatin
-
mutant T11_E18del-cathepsin H, pH 6.8, 30°C
-
0.00000053
chicken egg white cystatin
-
wild type enzyme, pH 6.8, 30°C
-
0.0032
N-benzoyl-3,5-diphenylpyrazoline
-
pH 7, 37°C
0.0032
N-benzoyl-3,5-diphenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00965
N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00965
N-benzoyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00144
N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00144
N-benzoyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00098
N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00098
N-benzoyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00127
N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00127
N-benzoyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.000174
N-formyl-3,5-diphenylpyrazoline
-
pH 7, 37°C
0.000174
N-formyl-3,5-diphenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.000135
N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.000135
N-formyl-5-(2-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.000387
N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.000387
N-formyl-5-(2-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.0000963
N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.0000963
N-formyl-5-(2-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.00013
N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.00013
N-formyl-5-(3-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.000272
N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.000272
N-formyl-5-(3-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.0000519
N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.0000519
N-formyl-5-(3-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.000137
N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.000137
N-formyl-5-(4-chlorophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.000221
N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.000221
N-formyl-5-(4-methoxyphenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.000058
N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
pH 7, 37°C
0.000058
N-formyl-5-(4-nitrophenyl)-3-phenylpyrazoline
-
in 0.1 M acetate buffer, at pH 5.0 and 37°C
0.0425
phenylacetyl hydrazine
-
at pH 7.0 and 37°C
0.0425
phenylacetyl hydrazine
-
pH 5, 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Lenney, J.F.; Liao, J.R.; Sugg, S.L.; Gopalakrishnan, V.; Wong, H.C.H.; Ouye, K.H.; Chan, P.W.H.
Low molecular weight inhibitors of cathepsins B, H and T in human serum, synovial fluid and CSF
Biochem. Biophys. Res. Commun.
108
1581-1587
1982
Homo sapiens
brenda
Barrett, A.J.; Kirschke, H.
Cathepsin B, Cathepsin H, and cathepsin L
Methods Enzymol.
80
535-561
1981
Homo sapiens, Rattus norvegicus
brenda
Lenney, J.F.; Tolan, J.R.; Sugai, W.J.; Lee, A.G.
Thermostable endogenous inhibitors of cathepsins B and H
Eur. J. Biochem.
101
153-161
1979
Homo sapiens, Paramecium caudatum, Rattus norvegicus, Sus scrofa, Tetrahymena pyriformis
brenda
Taniguchi, T.; Mizuochi, T.; Towatari, T.; Katunuma, N.; Kobata, A.
Structural studies on the carbohydrate moieties of rat liver cathepsins B and H
J. Biochem.
97
973-976
1985
Rattus norvegicus
brenda
Fuchs, R.; Machleidt, W.; Gassen, H.G.
Molecular cloning and sequencing of a cDNA coding for mature human kidney cathepsin H
Biol. Chem. Hoppe-Seyler
369
469-475
1988
Homo sapiens
brenda
Popovic, T.; Brzin, J.; Kos, J.; Lenarcic, B.; Machleidt, W.; Ritonja, A.; Hanada, K.; Turk, V.
A new purification procedure of human kidney cathepsin H, its properties ans kinetic data
Biol. Chem. Hoppe-Seyler
369
175-183
1988
Homo sapiens
-
brenda
Hara, K.; Kominami, E.; Katunuma, N.
Effect of proteinase inhibitors on intracellular processing of cathepsin B, H and L in rat macrophages
FEBS Lett.
231
229-231
1988
Rattus norvegicus
brenda
Ritonja, A.; Popovic, T.; Kotnik, M.; Machleidt, W.; Turk, V.
Amino acid sequences of the human kidney cathepsins H and L
FEBS Lett.
228
341-345
1988
Homo sapiens
brenda
Nishimura, Y.; Amano, J.; Sato, H.; Tsuji, H.; Kato, K.
Biosynthesis of lysosomal cathepsins B and H in cultures rat hepatocytes
Arch. Biochem. Biophys.
262
159-170
1988
Rattus norvegicus
brenda
Ishidoh, K.; Imajoh, S.; Emori, Y.; Ohno, S.; Kawasaki, H.; Minami, Y.; Kominami, E.; Katunuma, N.; Suzuki, K.
Molecular cloning and sequencing of cDNA for rat cathepsin H
FEBS Lett.
226
33-37
1987
Rattus norvegicus
brenda
Brmme, D.; Bescherer, K.; Kirschke, H.; Fittkau, S.
Enzyme-substrate interactions in the hydrolysis of peptides by cathepsins B and H from rat liver
Biochem. J.
245
381-385
1987
Rattus norvegicus
brenda
Rogers, J.C.; Dean, D.; Heck, G.R.
Aleurain: a barley thiol protease closely related to mammalian cathepsin H
Proc. Natl. Acad. Sci. USA
82
6512-6516
1985
Hordeum vulgare
brenda
Kominami, E.; Tsukahara, T.; Bando, Y.; Katunuma, N.
Distribution of cathepsins B and H in rat tissues and peripheral blood cells
J. Biochem.
98
87-93
1985
Rattus norvegicus
brenda
Willenbrock, F.; Brocklehurst, K.
Preparation of cathepsins B and H by covalent chromatography and characterization of their catalytic sites by reaction with a thiol-specific two-protonic-state reactivity probe
Biochem. J.
85
511-519
1985
Bos taurus
-
brenda
Takahashi, T.; Dehdarani, A.H.; Schmidt, P.G.; Tang, J.
Cathepsins B and H from porcine spleen
J. Biol. Chem.
259
9874-9882
1984
Sus scrofa
brenda
Takio, K.; Towatari, T.; Katunuma, N.; Teller, D.C.; Titani, K.
Homology of amino acid sequences of rat liver cathepsins B and H with that of papain
Proc. Natl. Acad. Sci. USA
80
3666-3670
1983
Rattus norvegicus
brenda
Bergmeyer, H.U.ed
Cathepsin B, cathepsin H, and cathepsin L
Methods Enzym. Anal. (3rd. ed. )
5
195-210
1984
Homo sapiens, Rattus norvegicus
-
brenda
Schwartz, W.N.; Barrett, A.J.
Human cathepsin H
Biochem. J.
191
487-497
1980
Homo sapiens, Rattus norvegicus
brenda
Singh, H.; Kalnitsky, G.
Separation of a new alpha-N-benzoylarginine-beta-naphthylamide hydrolase from cathepsin B1
J. Biol. Chem.
253
4319-4326
1978
Oryctolagus cuniculus
brenda
Sivaparvathi, M.; Sawaya, R.; Gokaslan, Z.L.; Chintala, K.S.; Rao, J.S.
Expression and the role of cathepsin H in human glioma progression and invasion
Cancer Lett.
104
121-126
1996
Homo sapiens, Rattus norvegicus
brenda
Aranishi, F.; Hara, K.; Osatomi, K.; Ishihara, T.
Substrate specificity of carp Cyprinus carpio cathepsin H with methylcoumarylamide substrates
Comp. Biochem. Physiol. B
116B
203-208
1997
Cyprinus carpio
brenda
Guncar, G.; Podobnik, M.; Pungercar, J.; Strukelj, B.; Turk, V.; Turk, D.
Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function
Structure
6
51-61
1998
Homo sapiens, Sus scrofa
brenda
Rothe, M.; Doth, J.
Studies on the aminopeptidase activity of rat cathepsin H
Eur. J. Biochem.
210
759-764
1992
Rattus norvegicus
brenda
Raghav, N.; Kamboj, R.C.; Parnami, S.; Singh, H.
Physico-chemical properties of brain cathepsin H
Indian J. Biochem. Biophys.
32
279-285
1995
Bos taurus
brenda
Aranishi, F.; Hara, K.; Ishinara, T.
Purification and characterization of cathepsin H from hepatopancreas of carp Cyprinus carpio
Comp. Biochem. Physiol. B
102B
499-505
1992
Cyprinus carpio
brenda
Yamamoto, K.; Kamata, O.; Kato, Y.
Separation and properties of three forms of cathepsin H-like cysteine proteinase from rat spleen
J. Biochem.
95
477-484
1984
Rattus norvegicus
brenda
Kominami, E.; Katunuma, N.
Immunological studies on cathepsins B and H from rat liver
J. Biochem.
91
67-71
1982
Rattus norvegicus
brenda
Kamphuis, I.G.; Drenth, J.; Baker, E.N.
Thiol proteases: comparative studies on the high-resolution structures of papain and actinidin, and on amino acid sequence information for cathepsins B and H, and stem bromelain
J. Mol. Biol.
182
317-329
1985
Homo sapiens
brenda
Vasiljeva, O.; Dolinar, M.; Turk, V.; Turk, B.
Recombinant human cathepsin H lacking the mini chain is an endopeptidase
Biochemistry
42
13522-13528
2003
Homo sapiens, Sus scrofa
brenda
Dodt, J.; Reichwein, J.
Human cathepsin H: deletion of the mini-chain switches substrate specificity from aminopeptidase to endopeptidase
Biol. Chem.
384
1327-1332
2003
Homo sapiens
brenda
Matsuishi, M.; Saito, G.; Okitani, A.; Kato, H.
Purification and some properties of cathepsin H from rabbit skeletal muscle
Int. J. Biochem. Cell Biol.
35
474-485
2003
Oryctolagus cuniculus
brenda
Jenko, S.; Dolenc, I.; Guncar, G.; Dobersek, A.; Podobnik, M.; Turk, D.
Crystal structure of stefin A in complex with cathepsin H: N-terminal residues of inhibitors can adapt to the active sites of endo- and exopeptidases
J. Mol. Biol.
326
875-885
2003
Sus scrofa
brenda
Brguljan, P.M.; Turk, V.; Nina, C.; Brzin, J.; Krizaj, I.; Popovic, T.
Human brain cathepsin H as a neuropeptide and bradykinin metabolizing enzyme
Peptides
24
1977-1984
2003
Homo sapiens
brenda
Froehlich, E.; Moehrle, M.; Klessen, C.
Cathepsins in basal cell carcinomas: activity, immunoreactivity and mRNA staining of cathepsins B, D, H and L. [Erratum to document cited in CA141:021292]
Arch. Dermatol. Res.
296
94
2004
Homo sapiens
-
brenda
Bratkovic, T.; Lunder, M.; Popovic, T.; Kreft, S.; Turk, B.; Strukelj, B.; Urleb, U.
Affinity selection to papain yields potent peptide inhibitors of cathepsins L, B, H, and K
Biochem. Biophys. Res. Commun.
332
897-903
2005
Homo sapiens
brenda
Horn, M.; Doleckova-Maresova, L.; Rulisek, L.; Masa, M.; Vasiljeva, O.; Turk, B.; Gan-Erdene, T.; Baudys, M.; Mares, M.
Activation processing of cathepsin H impairs recognition by its propeptide
Biol. Chem.
386
941-947
2005
Homo sapiens (P09668)
brenda
Chornaya, V.; Lyannaya, O.
Some physicochemical properties of cathepsin H from human meningioma
Exp. Oncol.
26
278-281
2004
Homo sapiens
brenda
Ueno, T.; Linder, S.; Na, C.L.; Rice, W.R.; Johansson, J.; Weaver, T.E.
Processing of pulmonary surfactant protein B by napsin and cathepsin H
J. Biol. Chem.
279
16178-16184
2004
Homo sapiens
brenda
Serveau-Avesque, C.; Ferrer-Di Martino, M.; Herve-Grepinet, V.; Hazouard, E.; Gauthier, F.; Diot, E.; Lalmanach, G.
Active cathepsins B, H, K, L and S in human inflammatory bronchoalveolar lavage fluids
Biol. Cell.
98
15-22
2006
Homo sapiens
brenda
Torikai, H.; Akatsuka, Y.; Miyazaki, M.; Tsujimura, A.; Yatabe, Y.; Kawase, T.; Nakao, Y.; Tsujimura, K.; Motoyoshi, K.; Morishima, Y.; Kodera, Y.; Kuzushima, K.; Takahashi, T.
The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303
Br. J. Haematol.
134
406-416
2006
Homo sapiens (P09668), Homo sapiens
brenda
Woischnik, M.; Bauer, A.; Aboutaam, R.; Pamir, A.; Stanzel, F.; de Blic, J.; Griese, M.
Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis
Eur. Respir. J.
31
1197-1204
2008
Homo sapiens (P09668), Homo sapiens
brenda
Lue, J.; Qian, J.; Keppler, D.; Cardoso, W.V.
Cathepsin H is an Fgf10 target involved in Bmp4 degradation during lung branching morphogenesis
J. Biol. Chem.
282
22176-22184
2007
Mus musculus
brenda
Nagaraj, N.S.; Santhanam, K.
Effect of frozen temperature and storage time on calpains, cathepsins (B, B + L, H and D) and their endogenous inhibitors in goat muscles
J. Food Biochem.
30
155-173
2006
Capra aegagrus
brenda
Yeh, H.Y.; Klesius, P.H.
Channel catfish, Ictalurus punctatus, cysteine proteinases: cloning, characterisation and expression of cathepsin H and L
Fish Shellfish Immunol.
26
332-338
2009
Ictalurus punctatus (B5LVX3), Ictalurus punctatus
brenda
Sethadavit, M.; Meemon, K.; Jardim, A.; Spithill, T.W.; Sobhon, P.
Identification, expression and immunolocalization of cathepsin B3, a stage-specific antigen expressed by juvenile Fasciola gigantica
Acta Trop.
112
164-173
2009
Fasciola gigantica (Q86MW6), Fasciola gigantica
brenda
Li, J.; Petrassi, H.; Tumanut, C.; Masick, B.; Trussell, C.; Harris, J.
Substrate optimization for monitoring cathepsin C activity in live cells
Bioorg. Med. Chem.
17
1064-1070
2009
Homo sapiens
brenda
D'Angelo, M.E.; Bird, P.I.; Peters, C.; Reinheckel, T.; Trapani, J.A.; Sutton, V.R.
Cathepsin H is an additional convertase of pro-granzyme B
J. Biol. Chem.
285
20514-20519
2010
Mus musculus
brenda
Buehling, F.; Kouadio, M.; Chwieralski, C.E.; Kern, U.; Hohlfeld, J.M.; Klemm, N.; Friedrichs, N.; Roth, W.; Deussing, J.M.; Peters, C.; Reinheckel, T.
Gene targeting of the cysteine peptidase cathepsin H impairs lung surfactant in mice
PLoS ONE
6
e26247
2011
Mus musculus
brenda
Raghav, N.; Garg, S.
N-formylpyrazolines and N-benzoylpyrazolines as novel inhibitors of mammalian cathepsin B and cathepsin H
Bioorg. Chem.
57
43-50
2014
Capra hircus
brenda
Singh, M.; Raghav, N.
2,3-Dihydroquinazolin-4(1H)-one derivatives as potential non-peptidyl inhibitors of cathepsins B and H
Bioorg. Chem.
59
12-22
2015
Capra hircus
brenda
Raghav, N.; Singh, M.
Acyl hydrazides and triazoles as novel inhibitors of mammalian cathepsin B and cathepsin H
Eur. J. Med. Chem.
77
231-242
2014
Capra hircus
brenda
Jevnikar, Z.; Rojnik, M.; Jamnik, P.; Doljak, B.; Fonovic, U.P.; Kos, J.
Cathepsin H mediates the processing of talin and regulates migration of prostate cancer cells
J. Biol. Chem.
288
2201-2209
2013
Homo sapiens
brenda
Lu, W.D.; Funkelstein, L.; Toneff, T.; Reinheckel, T.; Peters, C.; Hook, V.
Cathepsin H functions as an aminopeptidase in secretory vesicles for production of enkephalin and galanin peptide neurotransmitters
J. Neurochem.
122
512-522
2012
Bos taurus, Mus musculus
brenda
Raghav, N.; Singh, M.
SAR studies of differently functionalized chalcones based hydrazones and their cyclized derivatives as inhibitors of mammalian cathepsin B and cathepsin H
Bioorg. Med. Chem.
22
4233-4245
2014
Capra hircus
brenda
Garg, S.; Raghav, N.
2,5-Diaryloxadiazoles and their precursors as novel inhibitors of cathepsins B, H and L
Bioorg. Chem.
67
64-74
2016
Capra hircus (A0A060INS8)
brenda
Raghav, N.; Kaur, R.
Chalcones, semicarbazones and pyrazolines as inhibitors of cathepsins B, H and L
Int. J. Biol. Macromol.
80
710-724
2015
Capra hircus (A0A060INS8)
brenda
Naeem, A.S.; Tommasi, C.; Cole, C.; Brown, S.J.; Zhu, Y.; Way, B.; Willis Owen, S.A.; Moffatt, M.; Cookson, W.O.; Harper, J.I.; Di, W.L.; Brown, S.J.; Reinheckel, T.; O'Shaughnessy, R.F.
A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis
J. Allergy Clin. Immunol.
139
1228-1241
2017
Rattus norvegicus (P00786), Homo sapiens (P09668), Homo sapiens, Mus musculus (P49935), Mus musculus, Mus musculus C57BL/6J (P49935)
brenda
Raghav, N.; Kaur, R.
A comparative account of sar studies of semicarbazones and thiosemicarbazones on cathepsins H and L
Med. Chem. Res.
26
1723-1734
2017
Capra hircus (A0A060INS8)
-
brenda
Hao, Y.; Purtha, W.; Cortesio, C.; Rui, H.; Gu, Y.; Chen, H.; Sickmier, E.A.; Manzanillo, P.; Huang, X.
Crystal structures of human procathepsin H
PLoS ONE
13
e0200374
2018
Homo sapiens (P09668), Homo sapiens
brenda
Garg, S.; Raghav, N.
Inhibitory potential of some chalcones on cathepsins B, H and L
RSC Adv.
5
72937-72949
2015
Capra hircus (A0A060INS8)
-
brenda